COSCIENS Biopharma Other Current Liabilities

As of the most recent data (June 2024), AEZS shows a other current liabilities of $-900K. That compares with $160K in the prior-year period — down 672.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AEZS's other current liabilities is now $-900K (was $160K) — a 672.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether COSCIENS Biopharma is outperforming or lagging.

Tracking AEZS's other current liabilities over time shows whether COSCIENS Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-900K That compares with $160K in the prior-year period — down 672.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has COSCIENS Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $-900K) with ownership activity and broader fundamentals.

COSCIENS Biopharma's other current liabilities is $-900K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.